Oncology and Hematology News and Journal Articles
Surgical removal of primary breast cancer tumors had no benefit on overall survival in women who presented with metastatic breast cancer, according to the results of a study presented at SABCS.
Patients with HER2-positive breast cancer who achieved pathologic complete response had significantly improved event-free survival and overall survival over patients that did not, according to the trial results presented at SABCS.
A phase III trial of idelalisib plus rituximab in patients with previously treated chronic lymphocytic leukemia found that the combo improved progression-free and overall survival, according to results presented at the 2013 ASH meeting.
Patients with the rare and potentially deadly multicentric Castleman disease were able to achieve durable tumor and symptomatic response when assigned to treatment with the monoclonal antibody siltuximab, according to data presented at the 2013 ASH meeting.
The combination of lenalidomide plus dexamethasone demonstrated an improvement in both response rate and survival in newly diagnosed multiple myeloma patients not eligible for a stem cell transplant, according to data presented at the 2013 ASH meeting.
Patients aged 70 years or older had similar survival outcomes compared to their younger counterparts when undergoing nonmyeloablative, related haploidentical bone marrow or peripheral blood stem cell transplants for the treatment of hematologic malignancies, according to the results of a study presented at the 2013 ASH meeting.
Ponatinib showed significant antileukemic activity in patients with CML and ALL, according to a phase II study that included a wide range of disease stages and mutation status; patients in the trial had a relatively high rate of adverse thrombotic events, an issue which has led to recent regulatory controversy surrounding the drug.
In a 12-patient multiple myeloma pilot study, researchers demonstrated that anti-CD3 and anti-CD20 bispecific antibody (CD20Bi) activated both cellular and humoral anti-myeloma immunity that was detectable after patients received an autologous stem cell transplant.
In a late-breaking abstract presentation, Thorsten Klampfl, PhD, of the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna, presented data from a whole exome study of primary myelofibrosis patients, identifying a new specific molecular mutation
In this video, Dr. Mikhael discusses the current treatment paradigm for multiple myeloma and highlights some of the new agents in development.
At ONS Congress 2013, Peggy Scott explains how chemotherapy education classes at The Emily Couric Cancer Center, now in place for 2 years, have put patients at the center of their care and prepared them to start treatment (abstract 129532).
In this interview we discuss advances in whole-genome analyses, as well as novel blood-based assays in development to help diagnose and follow cancer patients through their treatment.
As part of our coverage for the 2013 American Society of Hematology Annual Meeting and Exposition, we discuss some of the research that will be highlighted during this year’s meeting.
In this podcast, we discuss whether all male colorectal cancer patients over the age of 60 should be screened for prostate cancer.
At the 10th International Congress of the Society for Melanoma Research (SMR), we spoke with Dr. Georgina Long about current targeted approaches for the treatment of advanced-stage melanoma.